The Patriot Institute
of Neurological Regeneration℠
Statement of Purpose
The Patriot Institute of Neurological Regeneration℠ has developed 10 distinct protocols for treating a wide range of neurological degenerative disorders. The PINR, a Non-Profit Organization, was officially formed April 30, 2026 to specifically target patients with physical impact related brain damage.
Our formation is the result of finding success during years of direct experience developing protocols for neurological disorders. J. Matthew, our CEO and post-doctoral candidate, endured a dozen failed bio/pharmaceutical treatments attempting to repair "permanently damaged" brain cells. Dr Matthew found a promising investigational-only, FDA unapproved 351a biologic, that has been studied in humans across 100's of peer reviewed journals over the past 10-12 years.
Read more...
Supporting our Q4-2026 Phase 1/2 Clinical Trial:
Case Study of 28 "Highly Suspected CTE" patients The Matthew CTE Treatment Protocol (2025-2026)
Our founder & CEO, afflicted with TBI's & Post-Concussive Syndrome himself, traveled across the United States in 2022-2025 visiting over 200 manufacturers that claimed to manufacture MSC-Exosomes. This promising experimental biologic is currently unapproved by the FDA; they are classified as 351a-category biologics that require much more testing in FDA approved clinical trials. But preclinical findings show a promising ability to regenerate dormant cells. But the unapproved nature combined with the theoretical possibility that MSC-Exosomes can repair almost any human injury.
Why the FDA has been very careful, and placed a whole team to monitor, mesenchymal Exosomes. Of the 250+ Manufacturer's to date (Sept 2026), the FDA only recognizes three manufacturers, total, making consistent high quality (minimally processed) MSC-Exosomes proven to be safe with minimal side effects. Utilizing any MSC-Exosomes who do not send all of their COA-Analysis' & clean room logs for every batch CAN LEAD TO SERIOUS SIDE EFFECTS.
Leveraging longstanding relationships within Neuro-Oncology & Neuro-Surgery colleagues across California, Arizona, Nevada, Massachusetts, Georgia, New York, & Hawaii we were able to identify 28 patients who met our strict criteria for 'Suspected CTE' & Severe TBI'. This case study utilized FDA Compliant requirements for every step of this research trial. Data was collected & managed by a 3-rd party CRO, we will have 9-month (median) follow-up data October 2nd, 2026. We utilized an Electronic Data Management System that eliminates data entry burn out by the doctors treating patients
CASE STUDY (2025-2026): 28-patients with "Highly Suspected CTE*" received The Matthew CTE Treatment Protocol: RESULTS (Median Follow up 6 months [July 2, 2026]:
A] 15 Patients were diagnosed with radiologically confirmed Traumatic Brain Injuries.
B] 13 Patients were diagnosed with Suspected Chronic Traumatic Encephalopathy.
C] 82% (23 of 28) total, for both groups, achieved a Partial Response (50% reduction in total symptoms*)
D] Suspected CTE group (n=13): 69% (n=9) achieved a Partial Response (Med = 6-mos).
E] Suspected CTE group (n=13): 46% (n=6) achieved a Complete Response* (Med = 6-mos).
F] Traumatic Brain Injury group (n=14): 93% (n=13) achieved a Partial Response (Med = 6-mos)
G] Traumatic Brain Injury group (n=14): 57% (n=8) achieved a Complete Response (Med = 9-mos)
E] Conclusion: Alcohol use was directly linked to treatment failure. For FDA IND-Application we will add "Alcohol Use During 90-day Treatment Window" as exclusion criteria. Preventing Alcohol drinking for 3-months is a priority.
Patient improvement was noted across numerous measures. These include, but are not limited to: Patient & caregiver standardized reports testing Neurological Function (ex: The Mini-Mental Exam). Plus we added wearable technology (headphones + ring + wristband) to provide diagnostic results. Wearable technology represents the future of clinical trials; having diagnostic data showing each patients Sleep, Heart Rate, Body Temperature, Oxygen Saturation, Physiological Stress, & daily EEG readings; we can monitor sleep quality, brain activity, physiological stress, & mood.
We worked with our Electronic Data Management company to develop concise 1-page check boxes that eliminates investigator reporting fatigue. Our Patient Informed Consent was built into the EDM system to allow for easy signing in the waiting room (if not completed at home). The Physicians Intent to Treat forms were also implemented in the EDM. Each patient was given precise instructions to dial 911, or visit closest ER, immediately if adverse events appear.Our Independant CRO followed up with each office that missed data entry. This resulted in a phenomenal 95% data completion.
For more information about The 28-patient CTE Treatment case study, click below to email our clinical trials team:
CTE is a destructive, debilitating, disease due to repeated/consistent head trauma from:
(1) Playing contact sports:
Boxing, American Football, Ice Hockey, Mixed Martial Arts Fighting, Soccer from headers, Rugby, Australian Rules Football);
(2) Serving in the Military:
Veterans exposed to blast zones and physical head trauma during battle result in TBI's. Traumatic Brain Injuries become CTE if the repeated head trauma is not stopped.
(3) Victims of Domestic Abuse:
Females & children develop Traumatic Brain Injuries much more easily than a 220+ pound American football player (Ann Mckee, MD Boston University CTE Center). Repeated hits to the head, over time, have been documented to transform into CTE (Lancet Neurology, 2026).
Read more...
Considering Suicide, PLEASE pause...and speak to a crisis team member. No waiting on hold and no AI bots!
PIECING TOGETHER A CTE DIAGNOSIS
As of Q1, 2026 new 7-T Magnetic Resonance Images [MRI] have been installed, for clinical and research use, at 100 key imaging sites across the US. Previously 3-T MRI's were the strongest imaging we had available.
Advancements in the detail obtained by 7-T MRI Images can display these radiological markers consistent with Neurological Degenerative diseases like Alzheimer's Disease & Chronic Traumatic Encephalopathy (CTE). For example:
- features of diffuse axonal injury (e.g. micro-hemorrhages) are visible now
- generalized cortical atrophy
- hippocampal atrophy
- vermian atrophy
- cavum septum pellucidum can all be seen much easier on new MRI equipment.
By adding results from a high-powered 7-T MRI, prior to randomization will be combined with all other intake qualifications to find a clear picture of who qualifies with "Suspected CTE" or Severe TBI's. Each patient will also have follow-up T-7 MRI's at months: 6, 12, 18, & 24.
Each patient will be provided Virtual Reality Goggles to keep them still, and distracted, for the 6-7 hour treatment cycles. The same protocol is used for TBI & CTE; with CTE patients receiving twice the dose.
Want to find out more? Please enter basic contact information on our HIPAA secure form:
Please Indicate which neurolgical condition you need information for.
Contact Form
We will get back to you as soon as possible.
Please try again later.
Impact-Related Brain Injuries
Neurological Degenerative Diseases
A Note From Our CEO
We do not sell, endorse, or sponsor any product, drug, or biologic. We are medical doctors but we aren't your doctor until you sign a form assigning us as your CTE/TBI Neurology Specialist.
As a Non-Profit Organization, we raise funding to cover the entire cost of treatment through scientific and research grants. When our 301(c)(3) tax exempt status is approved by the IRS; we will be able to accept the generous funding we've already secured. These Grants fund the entire treatment cost of the Matthew CTE or TBI Treatment Protocol (including transportation). All Clinical Trial Patients will receive treatment at zero cost to them. Once we are able to accept grant funds; we will begin randomizing patients for enrollment into this landmark clinical trial. Read more...